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Photodynamic therapya photosensitizer is critical to its therapeutic outcome during photodynamic
therapy (PDT). We delineated the distribution of hypericin, a new generation photosensitizer, in model
membrane systems to identify the operating principles of its subcellular accumulation. Results from
ﬂuorescence microscopy indicated preferential incorporation of hypericin in lipid of giant unilamellar
vesicles. Monolayer ﬂuorescence measurements further identiﬁed cholesterol as the key determinant for the
observed selectivity of hypericin. The emission spectra of hypericin in lipid monolayers varied in a lipid-
dependent manner and Stoke's shift behavior suggests that hypericin may form closely packed structure with
cholesterol. Overall, our data lead to the conclusion that cholesterol is the major origin of the selectivity for
hypericin in membrane systems. A hypothetical model depicting the intracellular and intravascular co-
transport of hypericin and cholesterol because of their high afﬁnity is presented.
© 2009 Elsevier B.V. All rights reserved.1. IntroductionPhotodynamic therapy (PDT) is a relatively new and prominent
treatment modality amongst the contemporary medical therapies for
cancer and viral diseases. PDT encompasses systemic administration of a
photosensitizer, followed by targeted delivery of an excitation light to the
site of lesion. By controlling the magnitude of light exposure, a locally
generated reactive oxygen species (ROS)would lead to eradication of the
tissue target. Because the therapeutic effects of PDT are based on
photochemical reactions between photosensitizing agents and light, a
proper and effective photosensitizer is crucial for its therapeutic efﬁcacy.
In addition, since ROS can only act closely to the site of its generation
because of its short half-life [1], the extent of photodamage in a cellwould
greatly depend on the subcellular localization of the photosensitizer.
Determining the principal sites and governing rules of subcellular
accumulation of a photosensitizer is therefore essential to PDT.
Hypericin (Fig. 1), a naturally occurring lipid soluble chromophore
extracted from Hypericum perforatum (commonly known as St John's
wort), is widely used as a dietary supplement against mild to
moderate depression. Because of its photo-induced cytotoxic effects
and low genotoxicity [2], hypericin has received renewed interest in
recent years, and is currently regarded as a new generation
photosensitizers in PDT or photodynamic diagnosis (PDD). Hypericin
is now known to exhibit antiviral [3–5], anticancer [5,6], and anti-
angiogenic [7,8] activities against infectious, neoplastic, and ophthal-ional Chung-Hsing University,
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ll rights reserved.mologic diseases. Similar to many clinically used or laboratory tested
photosensitizers, hypericin has been reported to localize in various
cellular or subcellular compartments, including plasma membrane,
endoplasmic reticulum (ER), mitochondria, lysosome, and Golgi
apparatus [6,9,10]. Nonetheless, the reported subcellular distributions
of hypericin appear to be diverse and elude conclusion [5,6]. For
example, hypericin has been shown to accumulate in membrane-
enclosed cytoplasmic organelles, including ER and Golgi complex, but
sparing mitochondria [11–13]. Other studies suggest mitochondria as
the primary target of hypericin phototoxicity [14].
Whether hypericin induces necrosis or apoptosis following PDT
depends on its subcellular localization. Thus, hypericinwhich localizes
inmitochondria leads to apoptotic cell death [9,15]. On the other hand,
concentrated hypericin in either plasma membrane or lysosomes
delays the apoptotic process and predisposes cells to necrosis [16,17].
Since targeting behavior of hypericin plays an essential role in its
phototoxic outcome, pinpointing the transport properties of hypericin
has been of great interests. However, whether the cellular uptake of
hypericin relies mainly on passive processes like diffusion and
solubility [18] or through membrane transport pathway (such as
endocytosis or pinocytosis) [19] is still unsettled. The association
between transport behavior of hypericin and determinants of its
subcellular localization therefore require further investigation.
The subcellular distribution of a photosensitizer in the cell is
usually attributed to chemical and physical features, including net
ionic charge, hydrophobicity (or hydrophilicity), and molecular
symmetry [10]. As such, the lipophilic property of hypericin should
predispose it to preferential binding with the lipid matrix of the cell
membrane [11]. However, the exhibition of cell type dependence by
Fig. 1. Chemical structure of hypericin.
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compositions of membrane lipids should play a crucial role in
determining hypericin's destination. Since membrane is stipulated
to be the principal cellular targets of hypericin [21], we predict that
transportation and incorporation of hypericin are related to the
properties and behaviors of membrane lipids. The selectivemembrane
targeting behavior of biomolecules is known to be associated with
phase separation behavior of membrane lipids that would result in
membrane microdomain formation [22,23]. An example is raft, which
is typically rich in saturated lipids and cholesterol and as such can be
the major determinant factor for biomolecule redistribution in
membranes [24]. Likewise, the selective localization of hypericin in
the cell might also be dependent on the preferential partition of
hypericin in speciﬁc assemblies of lipids.
In this work, giant unilamellar vesicles (GUVs) with lipid contents
displaying phase separated domains are used to model lipid raft
systems for the investigation of preferential localization of hypericin
within lipid membrane assemblies. Our results revealed that localiza-
tion of hypericin in GUVs was selective and the modeled raft domains
exhibited higher afﬁnity for hypericin. Observing from emission
spectroscopy and ﬂuorescence microscopy of hypericin in lipid
monolayers, the origin of selectivity is deduced to be closely related
to cholesterol.
2. Materials and methods
2.1. Materials
1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 1,2-
dioleoyl-sn-glycero-3-phosphocholine (DOPC) were obtained from
Avanti Polar Lipids (Alabaster, AL). 1,2-Dimyristoyl-sn-glycero-3-
phosphocholine (DMPC), cholesterol, DC-cholesterol, hypericin,
chloroform, and methanol were purchased from Sigma-Aldrich (St.
Louis, MO). All lipidswere usedwithout further puriﬁcation. 2-(12-(7-
Nitrobenz-2-oxa-1,3-diazol-4-yl)amino)dodecanoyl-1-hexadeca-
noyl-sn-glycero-3-phosphocholine (NBD-HPC), a ﬂuorescent lipid
molecule, was obtained from Invitrogen (Eugene, OR). Water was
treated by NANOpure Diamond ultra-pure water puriﬁcation system
(Barnstead International, Boston, MA) that produced water with a
purity of up to 18.2 MΩ-cm. Lipid samples were dissolved in
chloroform/methanol 2:1 (v/v) at a concentration of approximately
0.2 mg/ml for preparing GUVs and in chloroform at a concentration of
about 1 mg/ml for preparing monolayers. Stock solutions of hypericin
were prepared in ethanol. Samples were further diluted from stock
solutions with water to the desired molar ratios for each experiment.2.2. Forming giant unilamellar vesicles
GUVs were prepared from the ternary lipid mixtures of DPPC,
DOPC, and cholesterol along with minute amount (less than 1%) of
ﬂuorescent lipid probe NBD-HPC. GUVs were obtained by following
the protocol of electroformation reported by Angelova et al. [25].
Samples were compartmentalized by placing a Teﬂon spacer sand-
wiched between two ITO glasses. An AC ﬁeld, with a frequency around
10 Hz and amplitude of few volts/mm, was applied between the two
ITO glasses. The incubation temperature used in this studywas around
50–55 °C. A thermal electric cooling/heating module was installed
under the sample incubation cell for controlling temperature.
2.3. Fluorescence microscopy
Visualizations of both GUVs and monolayers were performed by a
Nikon CFI60 optical microscope Eclipse 600 ﬂuorescence systemwith
a Spot RT Color cooled CCD (Diagnostic Instrument, Sterling Heights,
MI). An objective from Nikonmodel Plan EPI SLWD 50×with N.A. 0.45
was used for high magniﬁcation measurement. Special attention was
paid to the photographing of experimental systems containing both
NBD-HPC and hypericin. A band pass ﬁlter (510 nm–600 nm) was
used as the barrier ﬁlter for experiments that required capturing
images of NBD-HPC ﬂuorescence in the presence of hypericin. A
home-built mini Langmuir trough was mounted on the sample stage
of the Nikon microscope system for taking images of lipid monolayer
samples. The surface ﬂow of subphase was reduced via adjusting
subphase level of the trough during photographing.
2.4. Spectroscopic measurement of hypericin ﬂuorescence in lipid
monolayers
Emission spectrum of hypericin in lipid monolayers was measured
in a home-built micro spectroscopy system. A green diode laser of
532 nm wavelength was used as the excitation light source and the
laser beamwas focused into a home-built mini Langmuir trough with
a long work distance objective [Nikon ELWD 100× with numerical
aperture 0.8]. A 532 nm super notch plus ﬁlter (Kaiser Optical
Systems, Ann Arbor, MI) was adopted to serve for two objectives:
functions as an excitation ﬁlter for selectively reﬂecting the excitation
light towards the sample trough, and as a barrier ﬁlter for selectively
blocking the scattered laser light from the samples. Emission signal
from sample was focused and directed towards the monochromator
[SpectraPro-300i Model SP-308, Acton Research Corporation (now
Roper Industries, Inc.), Sarasota, FL]. A CCD [Model Sperc-10:256E,
Princeton Instrument (now Roper Industries, Inc.), Sarasota, FL] was
used for measuring the spectrum.
3. Results
3.1. Selective localization of hypericin in lipid bilayer GUV systems
We modeled the biological raft systems by adapting bilayer
membranes rich in cholesterol and saturated lipid (DPPC). Ternary
lipid mixtures, consisting of a saturated lipid (DPPC), an unsaturated
lipid (DOPC) and cholesterol, were used to construct phase separated
regions on GUVs for creating raft domains. Less than 1% of lipid
ﬂuorescence probe NBD-HPC, favorably excluded from the modeled
rafts, was applied in this study for contrasting rafts. Immiscibility
behavior of this ternary-lipid GUV was determined by ﬂuorescence
microscopy (Fig. 2) and it was shown that only a limited range of
mixture compositions can form observable micron-scale phase separa-
tion domains. According to the rounded smooth domain boundary
character, the phase separation is determined to be co-existence of two
liquid phases [26]. Since cholesterol is known to be responsible for the
lateral separation of lipid phases [27–30], the observed immiscible
Fig. 2. Miscibility plot of DPPC/DOPC/cholesterol ternary mixture giant unilamellar vesicles (with 1% NBD-HPC) determined by ﬂuorescence microscopy at 25 °C. Filled dots (●)
denote compositions showing the dark domains as separated bubbles, while the white domains are connected as shown in the upper inset picture. Open dots (○) represent
compositions showing the white domains as separated bubbles and the dark domains are the connected regions as shown in the lower inset picture. Half ﬁlled dots ( ) identify lipid
compositions exhibiting roughly equal surface areas of dark and white domains. Data points marked with an open triangle (Δ) represent compositions without the noted phase
separation domain. Dashed line (‐‐) represents equi-molar ratio of cholesterol/DPPC and dot-dashed (y‐‐) line indicates equi-molar ratio of cholesterol/DOPC.
1289Y.-F. Ho et al. / Biochimica et Biophysica Acta 1788 (2009) 1287–1295phases should therefore be domains different in cholesterol content.
This can be veriﬁed by results shown in the immiscibility plot (Fig. 2).
The dashed and dot-dashed lines stand for equi-molar ratios ofFig. 3. GUV ﬂuorescence images of 2:2:1 DPPC/DOPC/cholesterol (with 1% NBD-HPC) lipid m
GUVs. The bright domains are DOPC-rich regions and the dark domains (indicated by white
intensity pattern (A2) displays reverse contrast when compared with (A1). (B) Hypericin w
uptake by GUVs. (B1) and (B2) are images of NBD-HPC ﬂuorescence and hypericin ﬂuoresc
domains (indicated by white arrows). All images were captured at 23 °C at a size of 50 μmcholesterol/DPPC and cholesterol/DOPC, respectively. The region to
the right of the dashed line has a higher molar concentration of DPPC
than cholesterol. The region above the dot-dashed line has a higherixture with hypericin. (A) Hypericin was mixed with the lipid mixture before forming
arrows) are cholesterol/DPPC-rich regions (A1). The observed hypericin ﬂuorescence
as injected into the incubation cell that contains preformed GUVs for viewing hypericin
ence respectively; demonstrating hypericin concentrated in the DPPC/cholesterol-rich
×50 μm.
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immiscible phenomena were observed only in the region where DPPC
surpassed cholesterol. Interestingly, the line of cholesterol/DOPC equi-
molar ratio is consistent with the boundary of equal surface areas of
dark and white domains. Thus, this revealed that both regions
contained DPPC, with one phase rich in unsaturated lipid (DOPC) and
the other one rich in cholesterol. This ﬁnding agrees with previous
report [31]. In the following GUV studies, lipid mixture of DPPC/DOPC/
cholesterol in a 2:2:1 mixing ratio was selected. With this ratio, we
expect the phase separated cholesterol-richmodeled raft will form islet
domains “ﬂoat” on a continuum of DOPC-rich lipid matrix.
The phenomenon of hypericin preferential localization in mem-
brane is illustrated by adding hypericin into GUVs of ternary lipid
mixtures (Fig. 3). Fig. 3A displays images of GUVs with 5% of hypericin
premixed with lipid mixtures before forming GUVs. According to the
miscibility plot, NBD-HPC predominantly resides in domains poor in
cholesterol. Thus, the dark domains shown on GUVs represent the
regions of modeled rafts (Fig. 3A1). Although ﬂuorescent signal of
hypericin seems to spread all over GUVs (Fig. 3A2), the intensity
distribution is apparently not uniform. Higher intensity locales of
hypericin ﬂuorescence on GUVs are found consistently complemen-
tary to those of NBD-HPC, suggesting hypericin favors to reside in raft
domains rather than the liquid-disordered domains. Fig. 3B presents
evidence of selective partition of hypericin in GUVs. In the absence of
hypericin, GUVs were formed inside the incubation cell and the
temperature was set to a value below the immiscible transition point
for assuring the existence of raft domains. Before adding hypericin
into the incubation cell, NBD-HPC ﬂuorescence was imaged forFig. 4. GUV ﬂuorescence images of 2:2:1 DPPC/DOPC/cholesterol+5% hypericin (with 1%
were taken at 34 °C, which was above the immiscibility transition temperature. (B) As
temperature, immiscible domains were observed. The intensity patterns of NBD-HPC ﬂuoresc
the DPPC/cholesterol-rich domains (indicated by white arrows). The scale of captured imadifferentiating domains on GUVs (Fig. 3B1). During the experiment,
it was noticed that hypericin ﬂuorescence could be observed on GUVs
almost immediately following its addition. The resulting hypericin
partition is concluded to be differential according to the distinguish-
able ﬂuorescence intensity pattern on GUVs as illustrated in Fig. 3B2.
Hypericin presents higher afﬁnity towards the modeled rafts.
When hypericin was introduced at a temperature above the
immiscibility temperature, it diffused into the lipid moiety of GUVs
without causing any demixing in the lipid bilayers (Fig. 4A). The
temperature was then lowered to a value below the lipid miscibility
point, subsequently, lipid segregation occurred and hypericin was
found to build up higher concentration in cholesterol-rich regions (see
Figs. 4, B1 and B2). This implies differential partition of hypericin in
modeled membrane systems is related to the formation of rafts.
Cholesterol is regarded as the key ingredient for forming liquid-
ordered raft-like domains, however, it has now been demonstrated
that the immiscibility transition in lipid membranes can also be
promoted by sterol-like derivatives [26]. In this study, we did not
found observable effect on the immiscibility transition in the presence
of hypericin. This observation was further testiﬁed by substituting
cholesterol with hypericin, and no immiscibility transition was
detected in the lipid mixtures up to 20% of hypericin.
Although the preferential partition of hypericin towards the
modeled raft domains has been demonstrated, one further step is
carried out to delineate possible discrete roles of cholesterol and DPPC
3.2. Differential localization of hypericin in lipid monolayer systemsNBD-HPC). (A) Images of NBD-HPC ﬂuorescence (A1) and hypericin ﬂuorescence (A2)
the temperature was cooled to 20 °C, which was below the immiscibility transition
ence (B1) and hypericin ﬂuorescence (B2) suggest hypericin preferred to concentrate in
ges is 50 μm×50 μm.
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cholesterol/DPPC and the determinant factor resulting in the
selectivity was found to be cholesterol. Cholesterol and DPPC form
phase separated domains in monolayers; however, it is difﬁcult to
observe this phenomenon on GUVs through ﬂuorescence microscopy
[31]. Therefore, Langmuir monolayer systems were employed for this
intended purpose. It is noteworthy to mention that there are two
different regions of two-phase co-existence in the binary mixture of
cholesterol and DPPC; ﬁrst one is the co-existence of DPPC liquid
crystal (LC) phase and DPPC gel phase under low (less than 15%)
cholesterol content and second region is phase separation of DPPC and
cholesterol at high cholesterol content (15% and up). Hence, both pure
DPPC and DPPC/cholesterol binary mixture systems were tested in
this study. When hypericin was spread onto the air–water interface
with DPPC only, we found hypericin was uniformly distributed in the
lower surface pressure (LC) phase of DPPC. At the emerging of DPPC
gel domains (Fig. 5A1) that were driven by increasing the surface
pressure above transition point, a simultaneous exclusion of hypericin
from the DPPC gel phase region was also observed (Fig. 5A2). This
denotes the less ordered LC phase structure of DPPC tends to host
hypericin better than the more ordered gel phase structure.
Phase separation in cholesterol and DPPC mixture can be observed
only in the context of cholesterol/DPPC mixing ratio exceeds 1:6.
Growth of dark domains was observed as the fraction of cholesterol
increases with NBD-HPC ﬂuorescence; as a result, the dark and white
areas shown in Fig. 5B1 were identiﬁed to be domains of cholesterol-
rich and DPPC-rich, respectively. Fig. 5B1 displays phase separatedFig. 5. Fluorescence images of lipid monolayers. (A) Monolayer of DPPC+1% hypericin (w
ﬂuorescence are the gel phase regions of DPPC. (A2) Hypericin ﬂuorescence indicates hyperic
+16% cholesterol+4% hypericin (with 1% NBD-HPC). (B1) White domains, as indicated by N
cholesterol-rich regions. (B2) Hypericin ﬂuorescence image clearly shows hypericin is inclindomains formed in cholesterol/DPPC 1:5 mixture containing 4%
hypericin. This phase separated state is expected to be a two liquid
coexist region [32,33]. Fig. 5B2 displays concurrent occurrence of
hypericin ﬂuorescence with the cholesterol-rich domains. This reveals
DPPC-rich domains are less attractive to hypericin and concentration
of hypericin is prone to build-up in cholesterol-rich domains. This
phenomenon was also validated by injecting hypericin into the water
subphase of monolayer for observing the partition of hypericin in
monolayer. Result from the experiment also displayed more intense
hypericin ﬂuorescence in cholesterol-rich regions.
The distinctive feature of incorporating hypericin into different
lipid environment was examined by measuring the ﬂuorescent
spectral responses of hypericin. Owing to the mirror symmetry
nature between absorption and ﬂuorescence spectra (Fig. 6A) and
the difﬁculty in measuring absorption spectrum in monolayers,
ﬂuorescence spectroscopy was exploited in the monolayer system for
better signal contrast and resolution. The absorption spectrum of
hypericin in ethanol (Fig. 6A) contains two major visible absorption
peaks: So→S1 (wavelength around 590 nm) and So→S2 (wave-
length around 480 nm). These transitions are assigned to be the
π–π⁎ transitions polarized along the short and long axes of the
hypericin skeleton, respectively [34,35]. The So→S1 transition
contained several vibration levels with three major representative
absorption peaks at 591 nm (0 phonon), 547 nm (1 phonon), and
3.3. Lipid-dependent ﬂuorescence emission of hypericinith 1% NBD-HPC) at 55 Å2/molecule. (A1) The dark domains revealed by NBD-HPC
in was expelled from the ordered gel phase region of DPPC. (B) Monolayer of 80% DPPC
BD-HPC ﬂuorescence, are identiﬁed as the DPPC-rich regions and the dark domains are
ed to co-localize with cholesterol. The scale of captured images is 250 μm×250 μm.
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being potentially assigned to different origins of vibration states
[36,37], spreading within the region. To dissect the spectroscopic
properties of hypericin in lipid surroundings, all spectral responses
were measured in Langmuir monolayers. Three different types of
lipids were tested: saturated lipids (DPPC and DMPC), unsaturated
(DOPC) lipids, and cholesterol (cholesterol and DC-cholesterol). We
noted the major features of hypericin ﬂuorescence spectra observed
in all the lipids tested were similar to its monomer ﬂuorescence
spectrum [35], indicating hypericin is capable of dispersing itself into
different lipids in monomeric form. Although minor differences could
be drawn among spectra of hypericin in different lipids, the lipid-Fig. 6. Hypericin absorption and emission spectra. (A) Absorption (- - - -) and emission
(\) spectra of hypericin in ethanol. (B) Emission spectra of hypericin in monolayer of
cholesterol at an isotherm pressure of 0 mN/m (\) and ~50 mN/m (- - - -). (C)
Emission spectra of hypericin in DPPC monolayer at an isotherm pressure of 0 mN/m
(\) and ~50 mN/m (- - - -).
Fig. 7. Plots of the wavelengths of ﬁtted hypericin emission maxima versus the
monolayer speciﬁc areas of cholesterol (□), DC-cholesterol (●), DPPC (▿), DMPC (▴)
and DOPC (⊗). The lines connecting each symbol are guides of the eye.dependent behavior was more apparent in emission spectra as
responding to monolayer compression (Fig. 6B and C).
The ﬂuorescence spectra of hypericin were found to shift towards
longer wavelength upon compression of lipid monolayers. We
characterized the shifts by ﬁtting featured spectrum peaks with
Gauss functions using a data analysis and graphing software Origin
(OriginLab, Northampton, MA). Thewavelengths of main ﬂuorescence
maxima (0 phonon) obtained from the Gaussian ﬁts, plotted as
functions of monolayer speciﬁc areas, are summarized in Fig. 7. It is
noted that the differences in spectral responses seem associated with
the structural characteristics of the lipids. DMPC and DPPC have
saturated hydrophobic tails, and their monolayer structures are either
in the LC phase or gel phase. From the ﬁtting data of hypericin
emission spectra, signiﬁcant red shifts were observed in both the LC
and gel phase structures of phospholipids (Fig. 6C). The extent of the
wavelength shifts is approximately 4 nm. On the other hand, the
hydrophobic tails of DOPC are unsaturated, thereby, rendering its
structure to be isotropic liquid. Structurally distinct from the three
glycerophospholipids, the monolayer structure of cholesterol
(cholesterol and DC-cholesterol) is assigned as cholesterol phase in
this study for easy designation. Both the spectral changes in
cholesterol (Fig. 6B) and liquid phases were found to be relatively
limited (b1 nm), and the shifts in the liquid and cholesterol phases
were distinctively smaller than their counterparts in gel and LC
phases.
The spectra of hypericin in cholesterol phase and liquid phase are
different. This difference could be identiﬁed from the spectral
responses of hypericin in LC and gel phases. The measured zero
phonon ﬂuorescence wavelengths at zero surface pressure of different
monolayers are located around 596 nm, and their values gradually
shift and saturate around 600 nm as the pressure of monolayer
increased. This implies hypericin ﬂuorescence spectra in the liquid
phase remain the same as the low pressure ones of DPPC and DMPC,
even if the surface pressure of DOPC is increased to a relatively high
value (Fig. 7). On the other hand, the wavelengths of ﬂuorescence
maxima in cholesterol phase are similar to those in high pressure
status of DPPC and DMPC, even if the monolayer pressure of
cholesterol approximates zero (Fig. 7). Although there are a couple
of factors, such as polarity or H-bonding [35], which can affect the
positions of ﬂuorescence maxima, we found interesting information
from matching the red shift of hypericin ﬂuorescence with the
isotherms of corresponding lipid monolayers. Plotting the ﬂuores-
cence maxima of hypericin and the speciﬁc areas of lipids as functions
of monolayer pressures, the trends of ﬂuorescence spectrum shifts
1293Y.-F. Ho et al. / Biochimica et Biophysica Acta 1788 (2009) 1287–1295seem to follow the changes of monolayer surface pressure better than
the surface density (Fig. 8).
4. Discussion
We found in this study that the localization of hypericin in
modeled membrane is selective and the selectivity is closely
associated with the existence of raft domains, enriched in cholesterol
and saturated lipid, on the membranes. Hypericin is more concen-
trated in the orderedmodeled raft regions rather than the less ordered
domains rich in unsaturated lipid. The hydrophobicity of hypericin
does favor its incorporation with membrane systems; however, the
distinctive selectivity of hypericin is speculated to lie in its geometric
character. The major element for attracting hypericin was further
identiﬁed to be cholesterol by phase separated DPPC/cholesterol
monolayer experiments. This suggests that the abundance of
cholesterol in raft domains is the key of the observed hypericin
selectivity. The inquiry of why cholesterol attracts hypericin more
competently than other lipids was resolved by the emission spectrum
studies of hypericin in various lipids; the data reveals hypericin packs
with cholesterol effectively.
Hypericin and cholesterol molecules share common molecular
morphology of rigid planar conﬁguration. Therefore, the analogous
morphological feature being the driving factor for the preferential
localization is hypothesized by assuming the similarity in structures
could promote the formation of a preferred molecular complex. Since
the π electrons in the skeleton of hypericin are known to be
accountable for the observed ﬂuorescence emission, so the spectrum
should be sensitive to changes in the adjourning packing along the
planar orientation of hypericin [35]. This indicates ordered planarFig. 8. Co-plots of surface pressures and ﬁtted hypericin emission maxima versus speciﬁc ar
represent the ﬁtted hypericin emission maximameasured in DMPC (A), DPPC (B), DC-choles
between ﬁtted Gaussian peaks and the spectral maxima of raw data. Deviations in the ﬁttinalignment of the molecules should affect the emission spectrummore
effectively. A pronounced level of Stoke's shift in hypericin emission
spectra was observed in the cholesterol phase as compared to other
lipids. This implies interaction between cholesterol and the π
electron-rich aromatic moiety of hypericin is strong, highly suggesting
hypericin and cholesterol molecules could be aligned and stacked
along the planar direction. This deduction is further justiﬁed as
follows. The shifts in emission spectra cannot be directly related to the
variations in monolayer surface density, but they can be scaled to
match the corresponding pressure raises during compression (Fig. 8).
To be more precise, the trends of shift did agree with the surface
pressure changes during isothermal compression, but the values of
wavelength differ from lipids to lipids (Figs. 7 and 8). As disclosed by
the ﬂuorescence spectra, hypericin in glycerophospholipids (DPPC,
DMPC, and DOPC) have similar initial peak positions. But the
substantial disparity in the size of wavelength shifts among liquid,
LC, and gel phases shall originate from neither the differences in
surface pressure nor the monolayer density. In other words, longer
wavelength of observed hypericin emission spectral maxima is an
outcome of hypericin molecule being packed in ordered lipid
environment. As a consequence, high surface pressure and high
monolayer density of unsaturated glycerophospholipids were shown
to have little impact to the ﬂuorescence emission. The wavelength of
hypericin emission maximum in cholesterol phase at zero surface
pressure displayed comparable values to those in highly compressed
LC and gel phases. This indicates that, with or without external
compression, hypericin molecule behaves like already being closely
surrounded by cholesterol.
Based on the observations of high afﬁnity of hypericin for
cholesterol, a model describing the intracellular and intravasculareas of monolayer molecules. Solid lines (\) are surface pressure and ﬁlled symbols (■)
terol (C), and DOPCmonolayers (D). Error bars plotted in the ﬁgures indicate differences
g are smaller than the size of plotted symbols.
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cholesterol is proposed. The transport of cholesterol in membrane
systems is speculated to be either a diffusion or a receptor-mediated
process [38]. Our observation of instantaneous appearance of
hypericin ﬂuorescence on GUVs implies that hypericin is capable of
targeting membrane systems via diffusion and the process is rapid.
Therefore, it is highly likely that hypericinwould target lipid assembly
at their ﬁrst encounter. This signiﬁes that the observed transport
pathway of hypericin is subject to sample preparation protocols. As a
result, if hypericin is introduced from aqueous solution in in vitro
studies, then the plasma membrane of a cell are predicted to be the
major targets of hypericin at the initial stage. This can justify the
observed ﬂuorescence localization of hypericin in the plasma
membrane and cytoplasm of human cancer cells according to
immediate confocal laser scanning microscopy measurement [9]. It
is known that cholesterol will be transported between plasma
membrane and ER [40,41], suggesting that ER is more likely to be
the following target for hypericin. In this regard, transfer of subcellular
localization of hypericin frommembrane and cytoplasm sites to the ER
and Golgi apparatus after 1 to 2 h of incubation has been reported [9].
In this analysis, we predict the subcellular localization of hypericin
and PDT effect can be manipulated through proper selection of carrier
and control of time. If hypericinwere given to a lipoprotein-containing
living organism or a cell line, the high-cholesterol-content low density
lipoprotein (LDL) might render itself as a strong attracting target for
hypericin. This agrees with the speculation of LDL as a hypericin
carrier [39]. This also agrees with the report of Siboni et al. that LDL-
containingmedia do exhibit higher intracellular uptake of hypericin as
compared to other serum- or BSA-containing cell culture media [19].
Although hypericin does exhibit preferential binding toward choles-
terol-rich plasma lipoproteins, species-dependent behavior was
reported. Chen et al. described that hypericin is primarily associated
with LDL in human plasma, but binds to high density lipoprotein
(HDL) in mouse plasma [42]. This discrepancy can be ratiﬁed by the
cholesterol-mediated transport hypothesis. Although both LDL and
HDL are rich in cholesterol, LDL is speculated to possess higher
efﬁciency in associating hypericin because of higher cholesterol
content in its surface lipids [43,44]. The reported ﬂuorescence proﬁle
of hypericin in mouse plasmawas obtained 2 h after intravenous (i.v.)
administration of hypericin to mice. Thus, the highly efﬁcient
circulatory and metabolic processes of mice might allow hypericin
to be swept out with cholesterol by HDL. The 2-h duration offers a
reasonable interpretation for the observed higher hypericin levels in
mouse HDL. Our prediction is in agreement with the function of HDL
as a cholesterol scavenger which extracts cholesterol from cellular
membranes and reduces cholesterol in tissues. The time-dependent
phototoxicity outcome in Chen's report did provide valuable evidence
in supporting our argument. The most severe damage in mice's tumor
cells under PDT treatment occurred at 0.5 h and 1 h after i.v. injection,
while the effects would be signiﬁcantly reduced from 100% to 40% at
2 h duration. This can also justify why there was no cure observed if
the interval between i.v. injection and light exposure was longer than
6 h [42]. Supporting evidence to our hypothesis also comes from the
cell death results following PDT. If the cellular uptake of hypericin is
through the LDL pathway, then the initial subcellular locale of
hypericin is prone to be lysosome. The cell death observed in mouse
tumor cells is necrotic subsequent to PDT, which is consistent with
early reports of cell death type following hypericin localization in
lysosomes [16,17].
In conclusion, the present study revealed the preferential
incorporation of hypericin into model membrane systems. The
selectivity of model membrane with hypericin originates from its
tendency of forming stable packing structures with cholesterol in
monolayers and GUVs. It follows that whether membrane transport of
hypericin is by diffusion or receptor-mediated pathway would largely
depend on the ﬁrst hypericin–cholesterol encounter. Information onthe distribution and transport of cholesterol in living systems is
readily available; thus, scientists and clinicians can take this advantage
to construct guiding maps for utilizing hypericin as a photosensitizer
in achieving high speciﬁcity. Elucidating the intracellular distributions
of pharmaceuticals, particularly photosensitizers, lay the basis for
optimizing therapeutic or diagnostic effectiveness and minimizing
untoward adverse reactions. This hypothesis of cholesterol-mediated
hypericin selectivity may, therefore, have signiﬁcant biological
implications. However, the issues of whether hypericin can actually
trail with cholesterol require more in-depth studies. The delineation
of mechanisms underlying biological regulations of hypericin afﬁnity
and transport awaits further investigation to achieve highly selective
PDT or PDD with clinical applicability in the future.
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